MLR 1017
Alternative Names: MLR1017Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator
- Developer Melior Pharmaceuticals, Inc.
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in USA
- 28 Dec 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 30 Nov 2015 Preclinical trials in Parkinson's disease in USA (unspecified route)